CARIPRAZINE: NEUROENDOCRINE AND METABOLIC ASPECTS OF TOLERANCE IN PATIENTS WITH MENTAL DISORDERS
Abstract
The review article analyzes the data of scientific publications concerning the psychoendocrinological and metabolic problems of therapy with the modern third generation antipsychotic, cariprazine, in patients with schizophrenia and bipolar disorder. In a comparative aspect, data on the incidence and severity of individual anthropometric and biochemical indicators of neuroendocrine dysfunctions are presented. The data of comparative studies on the effect of individual antipsychotics in comparison with cariprazine, as well as different doses of the drug on the levels of prolactin, high density lipoproteins (HDL) and low density lipoproteins (LDL), glucose, triglycerides, as well as changes in body weight of patients with mental disorders, in particular, taking into account the age factor. The advantages of cariprazine in terms of safety and tolerability in relation to hyperprolactinemia (HP) and metabolic disorders are shown.
Keywords
cariprazine, schizophrenia, hyperprolactinemia, dyslipidemia, hyperglycemia, triglycerides, bipolar disorder, weight gain